Grit Biotechnology has raised over $60 million in a Series B financing round led by CICC, with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership, and existing investors. The funds will support the development of Grit Biotechnology’s Tumor-Infiltrating Lymphocyte (TIL) pipeline, including a pivotal Phase II trial for GT101 and next-gen gene-edited TIL products. The company’s core technology platforms, including StemTexp®, StaViral®, KOReTIL®, and ImmuT Finder®, have enabled the development of advanced TIL products for cancer treatment. GT101 is the fastest-developing TIL therapy in China and will enter a Phase II trial by the end of 2023.
Grit Biotechnology announced the completion of a Series B financing round, raising over 60 million USD. The investment was led by CICC with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership and existing investors Sherpa Healthcare Partners, Decheng Capital and Matrix Partners China.
The financing will support Grit Biotechnology’s Tumor-Infiltrating Lymphocyte (TIL) pipeline development, including the pivotal Phase II trial for GT101 and the advancement of next-gen gene-edited TIL products. Founded in 2019, Grit Biotechnology is a pioneering cell therapy company focused on delivering transformative cancer treatments. GT101 is currently the fastest-developing TIL therapy in China and will enter a Phase II trial by the end of 2023.
Grit Bio has four core technology platforms central to its TIL development: StemTexp®, StaViral®, KOReTIL® and ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform. These platforms have enabled the development of next-generation gene-edited TIL products.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
GT201, a genetically engineered TIL product by Grit Biotechnology, boosts T cell survival and function by expressing a vital membrane-bound cytokine. It surpasses traditional TIL therapies in proliferation, tumor-killing and persistence with reduced reliance on IL-2. GT201 IND is approved by CFDA and entered Phase I clinical trials.
GT316, Grit Biotechnology’s next-gen TIL product, enhances TIL performance through knock-out of immunoregulatory targets identified via ImmuT Finder® CRISPR/Cas9 screening. In PDX mouse models, GT316 effectively eliminates tumors supported by low-dose IL-2 support with minimal toxicity. It offers substantial clinical benefits compared to conventional TIL products and is currently in IIT clinical trials in China.
With 100+ experienced professionals and a 10,000 sqm GMP-level cell therapy manufacturing facility in Suzhou, China, Grit Bio is a leading player in cell therapy field in China aimed at expediting the development of GT101 and next-generation TIL pipelines and addressing the unmet medical needs of solid tumor patients.
Source: BioSpace